Indeed, therapies with anti-TNF were associated with better outcomes of COVID-19 in IBD patients who contracted SARS-CoV-2 infection [31] and active phases of IBD are associated with a more severe course of COVID-19 [32]. The gene discussed is TNF; the disease is inflammatory bowel disease.